| 0 (0%) | 11-30 07:31 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.34 | 1-year : | 2.1 |
| Resists | First : | 1.15 | Second : | 1.79 |
| Pivot price | 1.03  |
|||
| Supports | First : | 0.1 | Second : | 0.08 |
| MAs | MA(5) : | 0.69 |
MA(20) : | 0.95 |
| MA(100) : | 2.51 |
MA(250) : | 1.85 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 31.9 |
D(3) : | 36.4 |
| RSI | RSI(14): 25.4 |
|||
| 52-week | High : | 3.86 | Low : | 0 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ EGRX ] has closed above bottom band by 11.1%. Bollinger Bands are 17.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.65 - 0.65 | 0.65 - 0.66 |
| Low: | 0.59 - 0.6 | 0.6 - 0.6 |
| Close: | 0.64 - 0.65 | 0.65 - 0.66 |
Thu, 30 Oct 2025
Eagle Pharma (OTCMKTS: EGRX) extends stockholder rights plan to 2026; $20 exercise - Stock Titan
Thu, 16 Oct 2025
Eagle Pharmaceuticals Announces Availability of Unaudited Second Quarter 2025 Financial Statements - The Manila Times
Wed, 15 Oct 2025
Unaudited Q2 2025 financials available — Eagle Pharmaceuticals posts three- and six-month statements - Stock Titan
Wed, 17 Sep 2025
Annual Meeting Alert: Eagle Pharmaceuticals Releases Two Years of Audited Financials Ahead of October Meeting - Stock Titan
Mon, 31 Mar 2025
Major Cash Injection: Eagle Pharma Lands $69M Through Strategic Royalty Sale - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 11.6 (%) |
| Held by Institutions | 55.2 (%) |
| Shares Short | 351 (K) |
| Shares Short P.Month | 484 (K) |
| EPS | 0.34 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 19.25 |
| Profit Margin | 4.6 % |
| Operating Margin | 15.9 % |
| Return on Assets (ttm) | 6.6 % |
| Return on Equity (ttm) | 4.8 % |
| Qtrly Rev. Growth | -12.9 % |
| Gross Profit (p.s.) | 13.87 |
| Sales Per Share | 19.87 |
| EBITDA (p.s.) | 4.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | 38 (M) |
| PE Ratio | 1.42 |
| PEG Ratio | 0 |
| Price to Book value | 0.02 |
| Price to Sales | 0.02 |
| Price to Cash Flow | -0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|